Diabetes - Pipeline Insight, 2024

This “Diabetes - Pipeline Insight, 2024,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetes Understanding

Diabetes: Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.

Symptoms
The symptoms of Diabetes include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. Long-term complications of diabetes include retinopathy with potential loss of vision, nephropathy leading to renal failure, peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints, and autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular symptoms.

Diagnosis
A diagnosis of Diabetes is based upon a thorough physical examination, medical history, and a variety of specialized tests. The primary test used to diagnose both type 1 and type 2 diabetes is known as the A1C, or glycated hemoglobin test. Diabetes may be diagnosed based on A1C criteria or plasma glucose criteria, either the fasting plasma glucose or the 2-h plasma glucose value after a 75-g oral glucose tolerance test. Tests that can be used to establish the etiology of diabetes include those reflective of beta cell function and markers of immune-mediated beta cell destruction.

Treatment
Treatment of Diabetes typically includes diet control, exercise, home blood glucose testing, oral medication and/or insulin. Insulin is the main treatment for type 1 diabetes and people with type 2 diabetes can be treated with oral medication, but may also require insulin in some cases. Therapies that are used to treat individuals with Diabetes include thiazolidinediones, DPP-4 inhibitors, meglitinides, alpha-glucosidase Inhibitors, biguanides, sulfonylureas, bile acid sequestrants, GLP-1 receptor agonists, amylin analog, SGLT2 inhibitors, dopamine receptor agonists or combinatorial medicines.

Diabetes Emerging Drugs Chapters

This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetes Emerging Drugs

• Enavogliflozin - Daewoong

Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

• Golimumab - Janssen Biotech

Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFa. It inhibits soluble and transmembrane forms of TNF-a by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

Diabetes: Therapeutic Assessment

This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetes

There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

Phases

This report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Diabetes.

• In December 2019, University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk announced that they have entered into a five-year research collaboration where they will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes.

Diabetes Report Insights

• Diabetes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetes drugs?
• How many Diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daewoong Tradipitant
• Janssen Biotech
• Zealand Pharma
• Provention Bio
• Bio RestorativeTherapies
• Elevian
• Kamada
• Adocia
• Oramed Pharmaceuticals
• ImCyse
• Histogen
• Novo Nordisk
• Enthera
• ActoBio Therapeutics
• Japan Tobacco
• Avotres

Key Products

• Enavogliflozin
• Golimumab
• Dasiglucagon
• Teplizumab
• BRTX-100
• rGDF11
• Alpha-1 antitrypsin
• BC 222 Insulin Lispro
• Insulin oral
• IMCY-0098
• Emricasan
• Insulin icodec
• ENT-001
• AG019
• JTT-662
• AVT-001

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.